

Dr. Simon J. Walsh MD FRCP FSCAI

Director of Cath Lab, Mater Private Network Cork

1. Holck EN, Holm NR, Hillock-Smith D, Lindsay MM, Spence M, Erglis A, Menown IBA, Steigen T, Lone JH, Modrau IS, Niemalä M, Lassen JF, Oldroyd K, Stradins P, Walsh SJ et al. Ten-year all-cause mortality after percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main disease: Final results from the randomised, open-label NOBLE trial. In Press, *The Lancet*
2. Holck EN, Andreasen LN, Neghabat O, Laanmets P, Spratt JC, Bennett J, Biscaglia S, Calic S, Walsh S et al. Title: Optical Coherence Tomography versus Angiographic Guidance of True Unprotected Left Main Bifurcation Disease: An OCTOBER substudy. Under Review *EuroIntervention*
3. de Winter RW, Hoek R, Walsh SJ et al. PCI of Native Coronary Artery vs Saphenous Vein Graft After Prior Bypass Surgery *J Am Coll Cardiol*. 2026;87(3):269-282.
4. O'Callaghan D, Durand Rm Hanratty CG, Cuisset T, Vaquerizo B, Sinning J-M, O'Kane P, Coughlan JJ, Walsh S et al. A Prospective, Multicenter, Open Label Study Investigating the Implementation of a Standardized Algorithm for Coronary Calcification With Plaque Modification Using Ultrasound Guidance to Improve Procedural and Clinical Outcomes (CYCLOPES): Design and Rationale of the CYCLOPES Trial. *Catheter Cardiovasc Interv*. 2025 Dec 17. doi: 10.1002/ccd.70424. Online ahead of print.
5. Ezad SM, McEntegart M, Dodd M, Didagelos M, Sidik N, Li Kam Wa M, Pavlidis A, Weerackody R, Walsh SJ et al. Impact of Anatomical and Viability-Guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy. *J Am Coll Cardiol*. 2024 Jul 23;84(4):340-3500.
6. Perera D, Morgan HP, Ryan M, Dodd M, Clayton T, O'Kane PD, Greenwood JP, Walsh SJ, et al. Arrhythmia and Death Following Percutaneous Revascularization in Ischemic Left Ventricular Dysfunction: Prespecified Analyses From the REVIVED-BCIS2 Trial. *Circulation*. 2023 Sep 12;148(11):862-871 doi: 10.1161/CIRCULATIONAHA.123.065300.
7. Perera D, Ryan M, Morgan HP, et al; REVIVED-BCIS2 Investigators. Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction: A Prespecified Secondary Analysis of the REVIVED-BCIS2 Trial. *JAMA Cardiol*. 2023 Dec 1;8(12):1154-116
8. DeSilva K, Li Kam Wa ME, Wells T, Mozid A, Ladwaniec A, Hynes BG, Kotecha A, Ratib K, Bissau S, Amabile N, Deharo P, McEntegart M, Spratt JC, Diane F, Hogg M, Mailey JA, Walsh SJ et al. The everolimus eluting Synergy Megatron™ drug-eluting stent platform: Early outcomes from the European Synergy Megatron™ Implanters' Registry. *Catheter Cardiovasc Interv*. 2023 Dec;102(7):1222-1228.

9. Simsek B, Tajti P, Carlino M, Ojeda S, Pan M, Rinfret S, Vemmou E, Kostantinis S, Nikolakopoulos I, Karacsonyi J, Rempakos A, Dens JA, Agostoni P, Alaswad K, Megaly M, Avran 11 A, Choi JW, Jaffer FA, Doshi D, Karpaliotis D, Khatri JJ, Knaapen P, La Manna A, Spratt JC, Tanabe M, Walsh S, et al. External validation of the PROGRESS-CTO perforation risk score: Individual patient data pooled analysis of three registries. *Catheter Cardiovasc Interv.* 2023 Jan 8. doi: 10.1002/ccd.30551. Online ahead of print.
10. Simsek B, Carlino M, Ojeda S, Pan M, Rinfret S, Vemmou E, Kostantinis S, Nikolakopoulos I, Karacsonyi J, Quadros AS, Dens JA, Abi Rafeh N, Agostoni P, Alaswad K, Avran A, Belli KC, Choi JW, Elguindy A, Jaffer FA, Doshi D, Karpaliotis D, Khatri JJ, Khelinskii D, Knaapen P, La Manna A, Krestyaninov O, Lamelas P, Padilla L, de Oliveira PP, Spratt JC, Tanabe M, Walsh S, et al. Validation of the OPEN-CLEAN Chronic Total Occlusion Percutaneous Coronary Intervention Perforation Score in a Multicenter Registry. *Am J Cardiol.* 2023 Feb 1;188:30-35.
11. Simsek B, Tajti P, Carlino M, Ojeda S, Pan M, Rinfret S, Vemmou E, Kostantinis S, Nikolakopoulos I, Karacsonyi J, Dens JA, Agostoni P, Alaswad K, Megaly M, Avran A, Choi JW, Jaffer FA, Doshi D, Karpaliotis D, Khatri JJ, Knaapen P, La Manna A, Spratt JC, Tanabe M, Walsh S, et al. External validation of the PROGRESS-CTO complication risk scores: Individual patient data pooled analysis of 3 registries. *Int J Cardiol.* 2023 Mar 15;375:14-20
12. de Winter RW, Walsh SJ, et al. Percutaneous coronary intervention of native coronary artery versus saphenous vein graft in patients with prior coronary artery bypass graft surgery: Rationale and design of the multicenter, randomized PROCTOR trial. *Am J Cardiol.* 2023 Mar;257:20-29. 1
1. 3. Råmunddal T, Holck EN, Karim S, Eftekhari A, Escaned J, Ioanes D, Walsh S, et al. International randomized trial on the effect of revascularization or optimal medical therapy of chronic total coronary occlusions with myocardial ischemia - ISCHEMIA-CTO trial - rationale and design *Am J Cardiol.* 2023 Mar;257:41-50.
13. Creaney C, Walsh S et al. Clinical outcomes and OCT analysis after culotte stenting with 2nd and 3rd generation Everolimus-eluting stents: Two-year follow-up of the Celtic bifurcation study *Cardiovasc Revasc Med.* 2022 Apr 20:S1553-8389(22)00181-6. *Cardiovasc Revasc Med.* 2022 Apr 20:S1553-8389(22)00181-6.
14. Prottly M, Sharp ASP, Gallagher S, Farooq V, Spratt JC, Ludman P, Anderson R, McEntegart MM, Hanratty C, Walsh S et al. Defining Percutaneous Coronary Intervention Complexity and Risk: An Analysis of the United Kingdom BCIS Database 2006-2016 *JACC Cardiovasc Interv.* 2022 Jan 10;15(1):39-49
15. Banning AP, Serruys P, De Maria GL, Ryan N, Walsh S et al. Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study. *Eur Heart J.* 2021 Oct 7:ehab703. doi: 10.1093/eurheartj/ehab703. Online ahead of print.ehab703. Online ahead of print.
16. Kite A, Ladwiniec A, Owens CG, Chase A, Shaukat A, Mozid AA, O’Kane P, Routledge H, Perera D, Jain AK, Palmer N, Hoole SP, Egred M, Sinha MK, Cahill TJ, Candilio L, Anantharam B, Byrne J, Walsh SJ et al. Outcomes following PCI in CABG candidates during the COVID-19 12 pandemic: The prospective multicentre UK-ReVasc registry. *Catheter Cardiovasc Interv.* 2021 doi: 10.1002/ccd.29702
17. Karpaliotis D, Stoler R, Walsh SJ et al. Safety and efficacy of Everolimus-Eluting bioabsorbable Polymer-Coated stent in patients with long coronary lesions: The EVOLVE 48 study *Catheter Cardiovasc Interv.* 2021 DOI: 10.1002/ccd.29798

18. Osknes A, Cosgrove C Walsh SJ et al. Intravascular Lithotripsy for Calcium Modification in Chronic Total Occlusion Percutaneous Coronary Intervention. *Journal of Interventional Cardiology* 2021:1-6 DOI: 10.1155/2021/9958035
19. Cosgrove C, Hanratty CG, Hill JM, Mahadevan K, Mailey J, McEntegart M, O'Kane P, Sidik N, Strange JW, Walsh SJ et al. Intravascular lithotripsy for treatment of calcific coronary lesions in ST elevation myocardial infarction. *Catheter Cardiovasc Interv.* 2021 May 29. doi: 10.1002/ccd.29801
20. Mailey J, Ahmed M, Hogg M, Cosgrove C, Murphy JC, McNeice AH, Spratt JC, Spence MS, Walsh SJ. Initial Experiences of Percutaneous Coronary Intervention Using a New Generation Everolimus-eluting Stent Platform. *J Invasive Cardiol.* 2021 Oct;33(10):E784-E790.
21. Walsh SJ et al. Intravascular Healing is not Affected by Approaches in Contemporary CTO PCI: The CONSISTENT CTO Study. *JACC Cardiovasc Interv.* 2020 2;13(12):1448-1457
22. Holm NR, Mäkikallio T, Lindsay MM, Spence MS, Erglis A, Menown IBA, Trovik T, Kellerth T, Kalinauskas G, Mogensen LKH, Nielsen PH, Niemelä M, Lassen JF, Oldroyd K, Berg G, Stradins P, Walsh SJ et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. *Lancet.* 2020 Jan 18;395(10219):191-199
23. Ladwiniec A, Walsh SJ et al. Intravascular ultrasound to guide left main stem intervention: a sub-study of the NOBLE trial. *EuroIntervention.* 2020;16(3):201-209.
24. Cosgrove CS, Wilson SJ, Bogle R, Hanratty CG, Williams R, Walsh SJ et al. Intravascular lithotripsy for lesion preparation in patients with calcific distal left main disease. *EuroIntervention.* 2020 May 20;16(1):76-79
25. Chichareon P, Modolo R, Kawashima H, Takahashi K, Kogame N, Chang CC, Tomaniak M, Ono M, Walsh S et al. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI. *JACC Cardiovasc Interv.* 2020 Mar 9;13(5):634-646
26. Ono M, Chichareon P, Tomaniak M, Kawashima H, Takahashi K, Kogame N, Modolo R, Hara H, Gao C, Wang R, Walsh S et al. The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. *Clin Res Cardiol.* Clin Res Cardiol. 2020 Sep;109(9):1125-1139 13
27. Kinnaird T, Gallagher S, Spratt JC, Ludman P, de Belder M, Copt S, Anderson RA, Walsh SJ et al. Complex high-risk and indicated percutaneous coronary intervention for stable angina: Does operator volume influence patient outcome? *Am Heart J.* 2020 Apr;222:15-25
28. Yeoh J, Cottens D, Cosgrove C, Mallek K, Strange J, Anderson R, Wilson S, Hanratty C, Walsh S et al. Management of stent underexpansion using intravascular lithotripsy- Defining the utility of a novel device. *Catheter Cardiovasc Interv.* 2020 Jan 8. doi: 10.1002/ccd.28715. [Epub ahead of print]
29. Kawashima H, Gao C, Takahashi K, Tomaniak M, Ono M, Hara H, Wang R, Chichareon P, Suryapranata H, Walsh S et al. Comparative Assessment of Predictive Performance of PRECISE-DAPT, CRUSADE, and ACUITY Scores in Risk Stratifying 30-Day Bleeding Events *Thromb Haemost.* 2020 Jul;120(7):1087-1095.
30. Kawashima H, Tomaniak M, Ono M, Wang R, Hara H, Gao C, Takahashi K, Sharif F, Thury A, Suryapranata H, Walsh S et al. Safety and Efficacy of 1-Month Dual Antiplatelet

Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS). *Am J Cardiol.* 2020 Oct 13;S0002-9149(20)31088-2. doi: 10.1016/j.amjcard.2020.09.057. Online ahead of print.

31. Kawashima H, Hara H, Wang R, Ono M, Gao C, Takahashi K, Suryapranata H, Walsh S et al. Usefulness of updated logistic clinical SYNTAX score based on MI-SYNTAX score in patients with ST-elevation myocardial infarction. *Catheter Cardiovasc Interv.* 2020 Nov 11. doi: 10.1002/ccd.29383. Online ahead of print. PMID: 33175478
32. Vemou E, Quadros AS, Dens JA, Rafeh NA, Agostini P, Alaswad K, Avran A, Belli K, Carlino M, Choi JW, El-Guindy A, Jaffer FA, Karpaliotis D, Khatri JJ, Khelinski D, Knaapen P, La Manna A, Krestyaninov O, Lamelas P, Ojeda S, Padilla L, Pan M, de Oliveira PP, Rinfret S, Spratt JC, Tanabe M, Walsh S et al. In-stent CTO percutaneous coronary intervention: Individual Patient Data Pooled Analysis of Four Multicenter Registries. *JACC Cardiovasc Interv.* 2020 In Press
33. Walsh SJ et al. Safety and efficacy of the NovaCross microcatheter in facilitating crossing of chronic total occlusion coronary lesions: a multicenter, single-arm clinical trial. *Coron Artery Dis.* 2020 Nov;31(7):573-577
34. Budassi S, Zivelonghi C, Dens J, Bagnall AJ, Knaapen P, Avran A, Spratt JC, Walsh S et al. Impact of prior coronary artery bypass grafting in patients undergoing chronic total occlusion-percutaneous coronary intervention: Procedural and clinical outcomes from the REgistry of Crossboss and Hybrid procedures in FrAnce, the NetheRlands, BelGium, and UnitEd Kingdom (RECHARGE). *Catheter Cardiovasc Interv.* 2020 May 5. doi: 10.1002/ccd.28954. Online ahead of print.